feedback

Course Director

Stewart J. Tepper, MD, FAHS
Stewart J. Tepper, MD, FAHS

Geisel School of Medicine at Dartmouth
Hanover, New Hampshire

Faculty

Robert P. Cowan
Robert P. Cowan, MD, FAAN, FAHS

Stanford University School of Medicine
Stanford, California

Accredited by

Medical Learning Institute, Inc.

Activity Details

Credit Types:CME / MOC / CNE
Credit Amount:1.0 Credits
Release Date:2019-Apr-11
Expiration Date:2020-Apr-10
Estimated Time for Completion:60 minutes
Registration Required:No
Cost:Free of charge

Activity Description and Educational Objectives

Migraine, a common neurovascular brain disorder, represents a severe and widespread health problem. In recent years a number of novel therapies for the acute treatment and prevention of migraine have been developed. These include centrally acting serotonin (5HT1F) agonists and therapies directed against the calcitonin gene-related peptide (CGRP) ligand and its receptor. In this activity, based on a recent live symposium held in Denver, Colorado, experts in neurology briefly review how migraine can be identified in clinical practice, discuss the latest data on emerging therapies for the acute treatment of migraine, assess current data on approved and emerging anti-CGRP monoclonal antibodies for migraine prevention, and highlight key considerations for using these therapies in clinical practice.

Upon completion of this activity, participants will be able to:
  • Apply established screening tools and criteria for migraine diagnosis in clinical practice
  • Identify data on the efficacy, safety, and tolerability of established and emerging therapeutics for the acute treatment of migraine
  • Cite updated evidence on available and emerging therapies for the prevention of migraine
  • Employ strategies to integrate emerging therapies for acute treatment and headache prevention into personalized management plans for patients with migraine if/when these agents are approved in the future

Target Audience

This activity has been designed to meet the educational needs of pain management specialists, headache specialists, neurologists, primary care physicians, internal medicine physicians, nurses, and other clinicians involved in the management of migraine.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME/MOC/CNE credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME/MOC/CNE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: April 11, 2019 - April 10, 2020
Time to Complete: 60 minutes

Faculty and Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Other PVI associates who are in a position to have control over the content of this activity, do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/MOC/CNE activity during the past 12 months.

The associates of the Medical Learning Institute, Inc., the accredited provider for this activity, do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/MOC/CNE activity during the past 12 months.

Course Director

Stewart J. Tepper, MD, FAHS
Professor of Neurology
Geisel School of Medicine at Dartmouth
Hanover, New Hampshire

Stewart J. Tepper, MD, FAHS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Acorda Therapeutics; Alder BioPharmaceuticals, Inc.; Alexza; Allergan; AlphaSights Ltd.; Amgen Inc.; ATI; Axsome Therapeutics, Inc.; Biohaven; Cefaly; Charleston Laboratories, Inc.; DeepBench; Dr. Reddy’s Laboratories Ltd.; electroCore, Inc.; Eli Lilly and Company; eNeura Inc.; ExpertConnect; GlaxoSmithKline; GLG Pharma, Inc.; Guidepoint Global, LLC; Impel; Magellan Rx Management; Navigant Consulting, Inc.; Neurolief Ltd.; Nordic Biotech; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Reckner Healthcare; Satsuma Pharmaceuticals, Inc.; Scion NeuroStim LLC; Slingshot Insights; Sorrento Therapeutics, Inc.; Sudler and Hennessey; Supernus Pharmaceuticals, Inc.; Teva Pharmaceuticals USA; Theranica Bio-Electronics; Trinity Partners; Xoc Pharmaceuticals; and Zosano Pharma Corporation.
Stock Shareholder in ATI.
Other financial interest/relationship as Royalties from Springer.

Stewart J. Tepper, MD, FAHS, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: investigational or off-label therapies for the treatment of migraines.

Faculty

Robert P. Cowan, MD, FAAN, FAHS
Higgins Family Professor, Neurology & Neurological Science
Stanford University School of Medicine
Stanford, California

Robert P. Cowan, MD, FAAN, FAHS, has a financial interest/relationship or affiliation in the form of:
Consultant for Alder BioPharmaceuticals, Inc; Allergan; Biohaven; electroCore, Inc.; Eli Lilly and Company; GLG, Guidepoint Global, LLC; Impel; Novartis Pharmaceuticals Corporation; Satsuma Pharmaceuticals, Inc.; Supernus Pharmaceuticals, Inc.; Teva Pharmaceuticals USA; Theranica Bio-Electronics; Xoc Pharmaceuticals; and Zosano Pharma Corporation.
Grant/Research Support from Allergan and Teva Pharmaceuticals USA.
Advisory Board for Alder BioPharmaceuticals, Inc; Amgen; Biohaven; Teva Pharmaceuticals, Inc.; and Xoc Pharmaceuticals.
Other Financial or Material Support from Principle and Founder, BonTriage, Inc, ProMyHealth, LLC., and royalties from Oxford University Press; Penguin/Avery; and Springer.

Robert P. Cowan, MD, FAAN, FAHS, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: investigational or off-label therapies for the treatment of migraines.

Content Reviewers

John Vester, MD, has no financial interests/relationships or affiliations in relation to this activity.

Tracy L. Greene, MSN, RN, FNP-C, Lead Nurse Planner, has no financial interests/relationships or affiliations in relation to this activity.

Amita B. Patel, MSN, RN, AOCNP, NP-C, has no financial interests/relationships or affiliations in relation to this activity.

Medical Director

Kirk A. Tacka, PhD
PVI, PeerView Institute for Medical Education

Kirk A. Tacka, PhD, has no financial interests/relationships or affiliations in relation to this activity.

Disclaimer

The information provided at this CME/MOC/CNE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit, and Support

Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared with ABIM through the ACCME’s Program and Activity Reporting System (PARS). Blinded individual or aggregated participant data may be shared with the funder of the activity.

Nurses

Medical Learning Institute, Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Successful completion of this continuing nursing education activity will be awarded 1.0 contact hour(s).

Providership


This CME/MOC/CNE activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

About This CME/MOC/CNE Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

Copyright © 2000-2019, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.